Drug use for non-hepatic associated conditions in patients with liver cirrhosis

  • M. Isabel Lucena
  • Raúl J. Andrade
  • Gianni Tognoni
  • Ramón Hidalgo
  • Felipe Sanchez de la Cuesta
  • the Spanish Collaborative Study Group on Therapeutic Management in Liver Diseases
Pharmacoepidemiology and Prescription



To study the prescribing patterns of practising physicians for the most frequent non-hepatic associated conditions in patients with liver cirrhosis.


A multi-centre prospective observational study carried out in 25 Spanish hospitals. Inpatients admitted to gastrointestinal and liver units with a diagnosis of liver cirrhosis were included in five centrally assigned index days, between February and June 1999. Information was collected about pharmacological treatments used on admission and recommended at discharge.


Five hundred and sixty-eight in-patients with a diagnosis of liver cirrhosis (44% alcoholic cirrhosis) and an average number of 2.5 co-morbid conditions were studied: diabetes mellitus (30%), infectious disorders (24%), cardiovascular disease (20%) and active alcoholism (15%)—the most common associated conditions. Chlormethiazole, amoxicillin–clavulanic acid, paracetamol, gliblenclamide, lorazepam, captopril and tiapride were the drugs used most prevalently. The average prescribed daily dose was <1 defined daily dose per day for most medication classes hepatically handled except for calcium channel blockers.


The present study expands current knowledge of prescribing patterns for associated conditions in patients with underlying liver cirrhosis. Drug dosing was affected in general by the influence of age and hepatic disease on the disposition of drugs, but knowledge on drug selection needs further attention.


Pharmacoepidemiology Drug use Liver cirrhosis 



This study was in part supported by a research grant from Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria, FISS No. 00/1109 and from the Agencia Española del Medicamento. K. Shashok checked the use of English in the manuscript. Participating centres assembled by regions: Andalucia: Hospital Clínico Universitario, Málaga: J.M. Fraile, M.R. Cabello, R. Alcántara, M. García–Cortés—Coordinating centre. Hospital Torrecárdenas, Almeria: M.C. Fernandez, G. Pelaez, J.L. Vega, M. Casado; Hospital Ciudad de Jaen, Jaen: E. Baeyens, M. M. Colmenero; Hospital Puerta del Mar, Cadiz: F. Diaz, P. Rendon, M. Macias; Hospital Reina Sofia, Cordoba: M. de la Mata; Hospital Virgen de las Nieves, Granada: R. Martín–Vivaldi, F. Nogueras; Hospital Puerto Real, Cadiz: J. Perez–Moreno, J.M. Puertas; Hospital Nuestra Sra de Valme, Sevilla: Dr. M. Romero–Gomez, A. Guil, L.Grande; Hospital General de la Axarquia, Velez–Málaga, Málaga: F. Santalla; Hospital Clínico Universitario S. Cecilio, Granada: M.A. Lopez–Garrido, E. Cerilla, J. Salmerón; Aragon: Hospital Clínico Universitario de Zaragoza: M. Simón, M. Villar, A. Lago; Asturias: Hospital Central de Asturias, Oviedo: L. Rodrigo, A. Alvarez–Alvarez, M. García–Espiga; Pais Vasco. Hospital Nuestra Sra de Aranzazu, San Sebastian. M. Garcia Bengoechea, F. Escandi, A. Tejada; Islas Canarias: Hospital Insular Universitario, Gran Canaria: L. Garcia–Villarreal, E. Jiménez, A. Monescillo; Hospital Universitario deTenerife: E. Quintero; Cantabria: Hospital Marqués de Valdecilla, Santander: F. Pons, C. Almohalla, B. de las Heras–Arechavala; Cataluña: Hospital Universitario Germans Trias i Pujol, Barcelona: R. Planas, R. Durandez, M.C. Peña; Hospital Vall d´Hebron, Barcelona: A. Vallano, A. González, J. de la Lama, M. García; Hospital del Mar, Barcelona: C. Hernández–López, M. Farré, R. Solá; Hospital Clinic i Provincial, Barcelona: M. Bruguera, M. Sala; Madrid: Hospital Clínico San Carlos, Madrid: O. Mariscal, E. Vargas, A. Moreno, M. Diaz Rubio; Hospital 12 de Octubre, Madrid: T. Muñoz–Yagüe, I. Salces–Franco, J.A. Solís–Herruzo; Fundación Hospital Alcorcón, Alcorcón, Madrid: J. A. González–Martin, C. Fernandez, G. Cacho–Acosta; Comunidad Valenciana: Hospital General de Valencia: M. Diago, P. Carbonell, V. García; Hospital Arnau de Vilanova, Valencia: O. González López, R. Giner Durán, C. Martínez Lapiedra


  1. 1.
    Reichen J (1997) Prescribing in liver disease. J Hepatol 26[Suppl 1]:36–40Google Scholar
  2. 2.
    Williams RL (1984) Drugs and the liver: clinical applications. In: Pharmacokinetic basis for drug treatment. Benet LZ, Massoud N, Gambertoglio JG (eds) Raven Press, New York, pp 63–75Google Scholar
  3. 3.
    Rowland M, Tozer TN (1995) Clinical pharmacokinetics. Concepts and applications, 3rd edn. Williams and Wilkins, Philadelphia, pp 248–263Google Scholar
  4. 4.
    Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399–431PubMedGoogle Scholar
  5. 5.
    Lewis JH (2002) The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 1:159–172Google Scholar
  6. 6.
    Westphal J-F, Brogard J-M (1997) Drug administration in chronic liver disease. Drug Saf 17:47–73PubMedGoogle Scholar
  7. 7.
    Sokol SI, Cheng A, Frishman WH, Kaza CS (2000) Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 40:11–30PubMedGoogle Scholar
  8. 8.
    Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, the Spanish Collaborative Study Group on Therapeutic Management in Liver Disease (2002) Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 58:435–440CrossRefPubMedGoogle Scholar
  9. 9.
    World Health Organisation Collaborating Centre for drugs statistics methodology (1997) Anatomical Therapeutic Chemical (ATC) classification index including defined daily dose (DDDs) for plain substances. World Health Organisation, OsloGoogle Scholar
  10. 10.
    Whitcomb DC, Block GD (1994) Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272:1845–1850CrossRefPubMedGoogle Scholar
  11. 11.
    Zimmerman HJ, Maddrey EC (1995) Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol. Analysis of instances of therapeutic misadventure. Hepatology 22:767–773PubMedGoogle Scholar
  12. 12.
    Seifert CF, Lucas DS, Vondracek TG, Kastens DJ, McCarty DL, Bui B (1993) Patterns of acetaminophen use in alcoholic patients. Pharmacotherapy 13:391–395PubMedGoogle Scholar
  13. 13.
    Carvajal A, Martin–Arias LH (1996) Antipsychotic drugs In: Meyler´s side effects of drugs. Aronson JK, van Boxtel CJ (eds) Elsevier, Holland, pp 40–60Google Scholar
  14. 14.
    Mayo–Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA 278:144–151PubMedGoogle Scholar
  15. 15.
    George DK, Crawford DHG (1996) Antibacterial–induced hepatotoxicity. Drug Saf 15:79–85PubMedGoogle Scholar
  16. 16.
    García–Rodríguez LA, Stricker BH, Zimmerman HJ (1996) Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156:1327–1332CrossRefPubMedGoogle Scholar
  17. 17.
    Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez de la Cuesta F (2001) Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33:123–130CrossRefPubMedGoogle Scholar
  18. 18.
    Andrade RJ, Lucena MI, Fernandez MC, Vega JL, Camargo R (2001) Hepatotoxicity in patients with cirrhosis, an often unrecognized problem. Lessons from a fatal case related to amoxicillin/clavulanic acid. Dig Dis Sci 46:1416–1419CrossRefPubMedGoogle Scholar
  19. 19.
    van Kraaij DJ, Jansen RWMM, de Gier JJ, Gribnau FWJ (1998) Prescription patterns of diuretics in Dutch community-dwelling elderly patients. Br J Clin Pharmacol 46:403–407CrossRefPubMedGoogle Scholar
  20. 20.
    van Dijk KN, de Vries CS, van den Berg PB, Brouwers JRBJ, de Jong-van den Berg LTW (2000) Drug utilization in Dutch nursing homes. Eur J Clin Pharmacol 55:765–771CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • M. Isabel Lucena
    • 1
  • Raúl J. Andrade
    • 1
  • Gianni Tognoni
    • 2
  • Ramón Hidalgo
    • 3
  • Felipe Sanchez de la Cuesta
    • 1
  • the Spanish Collaborative Study Group on Therapeutic Management in Liver Diseases
  1. 1.Clinical Pharmacology Service and Liver Unit, Hospital UniversitarioSchool of Medicine, University of MálagaMálagaSpain
  2. 2.Istituto di Ricerche Pharmacologiche Mario NegriMilanItaly
  3. 3.Centro de CálculoUniversity of MálagaMálagaSpain

Personalised recommendations